Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00862277 · ClinicalTrials.gov registry record
Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® Vaccine
A clinical trial, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- 763
- Enrollment target
NCT00862277: Completed study, sponsored by Sanofi Pasteur, a Sanofi Company.
NCT00862277 is a clinical trial that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 763 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00862277 has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- 763 participants
- Enrollment target
Study Summary
To evaluate the persistence of bactericidal antibodies in adolescents and adults who received one dose of Menactra® vaccine approximately four to eight years earlier
Interventions
- BIOLOGICAL Menactra®
- BIOLOGICAL Menomune®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 763 participants |
| Start Date | 2008-12 |
| Est. Completion | 2009-12 |
What the finished NCT00862277 record still lists
NCT00862277 is an observational study that tracks outcomes without assigning an intervention. The registered 763 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Menactra® is the first listed.
NCT00862277 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00862277 about?
NCT00862277 is a clinical study titled "Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® Vaccine". To evaluate the persistence of bactericidal antibodies in adolescents and adults who received one dose of Menactra® vaccine approximately four to eight years earlier
What is the current status of trial NCT00862277?
This trial is currently completed. The enrollment target is 763 participants. The study started on 2008-12. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00862277?
The interventions under investigation include: Menactra® (BIOLOGICAL), Menomune® (BIOLOGICAL).
Who is sponsoring clinical trial NCT00862277?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04578665 · 764 participants · NA
Human-like Robotic Controllers for Enhanced Motor Learning
- NCT05579366 · 764 participants · Phase 1
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- NCT06419374 · 762 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- NCT03789552 · 765 participants · Phase 3
Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia